50P Efficacy and safety of pemigatinib in Chinese patients with unresectable, advanced/ recurrent or metastatic intrahepatic cholangiocarcinoma with FGFR2 fusion or rearrangement that failed to prior systemic therapy
2021
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI